SEC Form 4 · accession 0001562180-18-003075
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gil J Van Lunsen
Director
Period of report
Jun 20, 2018
Accepted (ET)
Jun 21, 2018 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 20, 2018 | M | 7,500 | $4.36 | A | 26,797 | D | |
| Common Stock | Jun 20, 2018 | M | 14,000 | $5.13 | A | 40,797 | D | |
| Common StockF2 | Jun 20, 2018 | S | 21,500 | $19.08 | D | 19,297 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $5.13 | Jun 20, 2018 | M | 14,000 | D | — | Oct 29, 2025 | Common Stock | 14,000 | 11,000 | D |
| Stock Option (Right to Buy)F4 | $4.36 | Jun 20, 2018 | M | 7,500 | D | — | Oct 24, 2022 | Common Stock | 7,500 | 0 | D |
Explanation of responses
- F1These trades were made pursuant to a Rule 10b5-1 trading plan.
- F2The price reported for these shares is the weighted average sale price of transactions made at prices from $18.86 to $19.36. Details of actual prices for shares sold are available from the Issuer upon request.
- F3Options vested on October 29, 2016.
- F4Options vested on October 24, 2013.